Trial Profile
A phase I randomized, multiple-dose, open-label study evaluating pharmacokinetics of various doses bupropion administered concomitantly dextromethorphan of AXS-05 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2018
Price :
$35
*
At a glance
- Drugs Bupropion/dextromethorphan (Primary)
- Indications Agitation; Depressive disorders; Major depressive disorder; Smoking withdrawal
- Focus Adverse reactions; Pharmacokinetics
- 09 Oct 2018 Results assessing pharmacokinetics and safety and tolerabillty of AXS-05 (Dextromethorphan/Bupropion), presented at the 31st Annual Congress of the European College of Neuropsychopharmacology.
- 13 Jan 2016 New trial record
- 19 Nov 2015 Results were published in the SEC Form 424B2 for Axsome Therapeutics.